Approved Ligands

InformationOzanimod (RPC1063) Ozanimod (RPC1063) is a selective oral S1P Receptor 1 modulator. Phase 3.TargetsS1P1R (Cell-free assay): S1P5R (Cell-free assay) 0.41 nM(EC50): 11 nM(EC50)In vitroIn S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R

InformationOzanimod (RPC1063) Ozanimod (RPC1063) is a selective oral S1P Receptor 1 modulator. Phase 3.TargetsS1P1R (Cell-free assay): S1P5R (Cell-free assay) 0.41 nM(EC50): 11 nM(EC50)In vitroIn S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R

InformationOzanimod (RPC1063) Ozanimod (RPC1063) is a selective oral S1P Receptor 1 modulator. Phase 3.TargetsS1P1R (Cell-free assay): S1P5R (Cell-free assay) 0.41 nM(EC50): 11 nM(EC50)In vitroIn S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R

InformationOzanimod (RPC1063) Ozanimod (RPC1063) is a selective oral S1P Receptor 1 modulator. Phase 3.TargetsS1P1R (Cell-free assay): S1P5R (Cell-free assay) 0.41 nM(EC50): 11 nM(EC50)In vitroIn S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R

InformationOzanimod (RPC1063) Ozanimod (RPC1063) is a selective oral S1P Receptor 1 modulator. Phase 3.TargetsS1P1R (Cell-free assay): S1P5R (Cell-free assay) 0.41 nM(EC50): 11 nM(EC50)In vitroIn S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R

InformationOzanimod (RPC1063) Ozanimod (RPC1063) is a selective oral S1P Receptor 1 modulator. Phase 3.TargetsS1P1R (Cell-free assay): S1P5R (Cell-free assay) 0.41 nM(EC50): 11 nM(EC50)In vitroIn S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R

InformationPacritinib (SB1518) is a potent and selective inhibitor ofJanus Kinase 2 (JAK2)andFms-Like Tyrosine Kinase-3 (FLT3)withIC50sof 23 and 22 nM in cell-free assays, respectively. Phase 3.TargetsFLT3 (D835Y) (Cell-free assay): JAK2 (V617F)

InformationPacritinib (SB1518) is a potent and selective inhibitor ofJanus Kinase 2 (JAK2)andFms-Like Tyrosine Kinase-3 (FLT3)withIC50sof 23 and 22 nM in cell-free assays, respectively. Phase 3.TargetsFLT3 (D835Y) (Cell-free assay): JAK2 (V617F)

InformationPacritinib (SB1518) is a potent and selective inhibitor ofJanus Kinase 2 (JAK2)andFms-Like Tyrosine Kinase-3 (FLT3)withIC50sof 23 and 22 nM in cell-free assays, respectively. Phase 3.TargetsFLT3 (D835Y) (Cell-free assay): JAK2 (V617F)

InformationPacritinib (SB1518) is a potent and selective inhibitor ofJanus Kinase 2 (JAK2)andFms-Like Tyrosine Kinase-3 (FLT3)withIC50sof 23 and 22 nM in cell-free assays, respectively. Phase 3.TargetsFLT3 (D835Y) (Cell-free assay): JAK2 (V617F)

Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.

Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.